HistoRx Extends Eli Lilly Deal for Biomarker Analysis Technology | GenomeWeb

NEW YORK (GenomeWeb News) – HistoRx said today that it has signed a three-year agreement to supply its biomarker analysis technology to drugmaker Eli Lilly and Company.

The company said it has extended and expanded a 2005 agreement to make its Aqua technology available to Lilly for use in its pharmaceutical development programs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.